Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Normothermic intraperitoneal carboplatin after cytoreductive surgery in elderly and fragile ovarian cancer patients
2025-522269-30-00Phase 2Authorised
- Sponsor
- University Hospital Odense
- Start
- Dec 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by University Hospital Odense. Primary endpoint: Safety of cytoreductive surgery combined with NIPEC carboplatin. Planned start Dec 2025; status: authorised.
02
Drugs
carboplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2025-522269-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522269-30-00.